Tocris Bioscience obtained exclusive rights from AstraZeneca to supply two anticancer agents, anastrozole and bicalutamide, as preclinical research compounds.  Anastrozole is an aromatase inhibitor, and bicalutamide is an androgen inhibitor.


“By making the fully licensed products available through our catalogue, we hope to promote new and exciting research in the fundamental processes that drive cancer development,” says Duncan Crawford, Tocris’ CSO.








This site uses Akismet to reduce spam. Learn how your comment data is processed.